Targeted radiotherapy of bone malignancies

Current Drug Discovery Technologies

Volumn 7, Issue 4, 2010, Pages 233-246

  Jansen, David R ^a   Krijger, Gerard C ^b,c   Kolar, Zvonimir I ^c   Zonnenberg, Bernard A ^d   Zeevaart, Rijn ^a,e  

^a NECSA   (South Africa)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Bone targeting; Bone pain palliation; Bone seeking; Hormone refractory prostate cancer; Metastasis; Radiopharmaceutical

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENE PHOSPHONATE; 6 HYDRAZINOPYRIDINE 3 CARBOXYLIC ACID CONJUGATED HYDROXYBISPHOSPHONATE TC 99M; [1 HYDROXYETHYLIDENE]DIPHOSPHONIC ACID RE 188; ALENDRONIC ACID; ANTINEOPLASTIC AGENT; CADMIUM 116; CAPECITABINE; ESTRAMUSTINE PHOSPHATE; ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID) LUTETIUM LU 177; GALLIUM 68; HYDROXYAPATITE; LEXIDRONAM SAMARIUM SM 153; LUTETIUM 177; MERCAPTOACETYLGLYCYLGLYCYLGLYCINE CONJUGATED HYDROXYBISPHOSPHONATE TC 99M; MITOXANTRONE; MONOCLONAL ANTIBODY CC49; PENTETIC ACID; PHOSPHONIC ACID DERIVATIVE; PREDNISONE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM 223; RADIUM 225; STRONTIUM 89; TIN 117; UNCLASSIFIED DRUG;

ANALGESIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUGER ELECTRON SPECTROSCOPY; BINDING AFFINITY; BONE CANCER; BONE DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMA; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DOSIMETRY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; DRUG UPTAKE; HUMAN; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOISOTOPE DECAY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERMODYNAMICS; TUMOR CELL;

ANIMALS; BONE NEOPLASMS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PAIN; PALLIATIVE CARE; QUALITY OF LIFE; RADIATION DOSAGE; RADIOPHARMACEUTICALS;

EID: 78650743143     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016310793360675     Document Type: Article

References (115)

1. Jarvis N, Wagener JM, Jackson GE. Metal-ion speciation in blood-plasma as a tool for elucidating the in-vivo behaviour of radiopharmaceuticals containing Sm-153 and Ho-166. J Chem Soc Dalton Trans 1995; 1411-5.
2. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000; 289(5484): 1508-14.
3. Liotta LA. Cancer: An attractive force in metastasis. Nature 2001; 410: 24-5.
4. Logothetis CJ, Navone NM, Lin S. Understanding the Biology of Bone Metatases: Key to the Effective Treatment of Prostate Cancer. Clin Cancer Res 2008; 14(6): 1599-602.
5. Yeh HS, Berenson JR. Treatment for myeloma bone disease. Clin Cancer Res 2006; 12: 6279-84s.
6. Roux S, Bergot C, Fermand JP, Frija J, Brouet JC, Mariette X. Evaluation of bone mineral density and fat-lean distribution in patients with multiple myeloma in sustained remission. J Bone Miner Res 2003; 18: 231-6.
7. Coleman RE. Management of bone metastases. Oncologist 2000; 5(6): 463-70.
8. Von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with emphasis on bisphosphonates. Support Care Cancer 2008; 16: 1105-15.
9. Tu S, Lin S. Current trials using bone-targeting agents in prostate cancer. Cancer J 2008; 14: 35-9.
10. Milecki P. Radiotherapy as a method of palliative treatment of bone metastases. Contemp Oncol 2002; 6(3): 173-6.
11. Toegel S, Hoffmann O, Wadsak W, et al. Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts. Eur J Nucl Med Mol Imaging 2006; 33(4): 491-4.
12. Das T, Chakraborty S, Sarma HD, et al. 170Tm-EDTMP: a potential cost-effective alternative to 89SrCl2 for bone pain palliation. Nucl Med Biol 2009; 36: 561-8.
13. Atkins HL, Mausner LF, Srivastava SC, et al. Biodistribution of Sn-117m(4+)DTPA for palliative therapy of painful osseous metastases. Radiology 1993; 186: 279-83.
14. Marshall JH. Radioactive hotspots, bone growth and bone cancer: self-burial of calcium-like hot-spots. In: McLean FC, Lacroix P, Bundy AM, Eds. Radioisotopes and Bone. Oxford, England: Blackwell Scientific 1962; pp. 35-50.
15. Logan KW, Volkert WA, Holmes RA. Radiation dose calculations in persons receiving injection of samarium-153 EDTMP. J Nucl Med 1987; 28: 505-9.
16. Maxon III HR, Schroder LE, Thomas SR, et al. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990; 176: 155-9.
17. Lass P. Radionuclide treatment of bone metastases-current concepts and trends. Nucl Med Rev 2001; 4(1): 1-3.
18. Tripathi M, Singhal T, Chandrasekhar N, et al. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Ind J Cancer 2006; 43(2): 86-92.
19. Nijsen JFW, Krijger GC, Van het Schip AD. The bright future of radionuclides for cancer therapy. Anti-cancer Agents Med Chem 2007; 7(3): 271-90.
20. Tse JW, Wiebe LI, Noujaim AA, High specific activity [Samarium-153] EDTA for imaging of experimental tumor models. J Nucl Med 1989; 30(2): 202-8.
21. Knapp FF Jr, Mirzadeh S, Beets AL, Du M, Klein JA, Garland M. Direct Production of Lutetium-177 from Enriched Lu-176 in a High Flux Reactor-The Only Practical Route to Provide High Specific Activity/Multi-Curie Levels of Lu-177. Required fro Routine Clinical Use. 5th International Conference on Isotopes (5ICI), Brussels, Belgium, April 24-29, 2005.
22. Knapp FF Jr. Future prospects for medical radionuclide production in the High Flux Reactor (HFIR) at The Oak Ridge National Laboratory (ORNL). Ann Nucl Med Sci 2001; 14: 109-18.
23. Moustapha ME, Ehrhardt GJ, Smith CJ, Szajek LP, Eckelman WC, Jurisson SS. Preparation of Cyclotron-Produced Re-186 and Comparison with Reactor-Produced Re-186 and Generator-Produced Re-188 for the Labeling of Bombesin. Nucl Med Biol 2006; 33(1): 81-9.
24. Bruland OS, Jonasdottir TJ, Fisher DR, Larsen RH. Radium-223: from radiochemical development to clinical applications in targeted cancer therapy. Curr Radiopharm 2008; 1 (3): 203-8.
25. Ponsard B, Srivastava SC, Mausner LF, Knapp FF, Garland MA, Mirzadeh S. Production of Sn-117m in the BR2 high-flux reactor. Appl Radiat Isot 2009; 67: 1158-61.
26. http://www.curativetechnologies.com/Sn117m.html
27. Abbas K, Buono S, Burgio N, et al. Development of an accelerator driven neutron activator for medical radioisotope production. Nucl Instrum Meth A 2009; 601: 223-8.
28. IAEA, Nuclear Technology Review, 2009.
29. Henriksen G, Fisher DR, Roeske JC, Bruland 0S, Larsen RH. Targeting of osseous sites with a-emitting 223Ra: Comparison with the β-emitter 89Sr in mice. J Nucl Med 2003; 44(2): 252-9.
30. Qaim SM, Dohler H. Production of Carrier-free 117mSn. Int J Appl Radiat Isot 1983; 35: 645-50.
31. Francis MD, Valent DJ. Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases. J Musculoskelet Neuronal Interact 2007; 7 (1): 2-8.
32. Zeevaart JR, Jarvis NV, Cukrowski I, Jackson GE. Blood plasma modelling of the in vivo behaviour of bisphosphonate-metal ion complexes as radiopharmaceuticals. S Afr J Chem 1997; 50(4): 189-94.
33. Zeevaart JR, Jarvis NV, Louw WKA, Jackson GE, Cukrowski I, Mouton CJ. Metal-ion speciation in blood plasma incorporating the bisphosphonate, 1-hydroxy-4-amino-propilydenediphosphonate (APD), in therapeutic radiopharmace-uticals. J Inorg Biochem 1999; 73: 265-72.
34. Thurlimann B, Morant R, Jungi WF, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 1994; 2(1): 615.
35. Degrossi OJ, Oliveri P, Del Rio HG, Labriola R, Artagaveytia D, Degrossi EB. Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent. J Nucl Med 1985; 26: 1135-9.
36. Silberstein EB. The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin Oncol 1993; 20(3): 1021.
37. Mikolajczak R, Parus JL. Reactor Produced Beta-emitting Nuclides for Nuclear Medicine. WJNM 2005; 4(3): 184-90.
38. Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simons J, Wilson D. Skeletal localization of Samarium-153 chelates: Potential therapeutic bone agents. J Nucl Med 1987; 28(4): 495-504.
39. Yen RF, Chen CY, Cheng MF, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Com-mun 2010; 31(7): 637-45.
40. Even-Sapir E, Metser U, Flusser F, et al. Assessment of Malignant Skeletal Disease: Initial Experience with 18F-Fluoride PET/CT and Comparison Between 18F-Fluoride PET and 18F-Fluoride PET/CT. J Nucl Med 2004; 45(2): 272-8.
41. Bhargava P, Hanif M, Nash C. Whole-body F-18 sodium fluoride PET-CT in a patient With renal cell carcinoma. Clin Nucl Med 2008; 33(12): 894-5.
42. Lacerda S, Marques F, Campello P, Gano L, Kubicek V, Hermann, P Santos I. Chemical, radiochemical and biological studies of Sm and Ho complexes of H4dota analogs containing one methylphos-phonic/phosphinic acid pendant arm. J Labelled Comp Radiopharm 2010; 53: 36-43.
43. Rill C, Kolar ZI, Kickelbick G, Wolterbeek HT, Peters JA. Kinetics and thermodynamics of adsorption on hydroxyapatite of the [160Tb]Terbium complexes of the bone-targeting ligands DOTP and BPPED. Langmuir 2009; 25(4): 2294-301.
44. Fellner M, Baum RP, Kubicek V, Hermann P, Lukes I, Prasad V. PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study. Eur J Med Mol Imaging 2010; 37: 834.
45. Torres Martin de Rosales R, Finucane C, Mather SJ, Blower PJ. Bifunctional bisphosphonate complexes for the diagnoses and therapy of bone metastases. Chem Commun 2009: 4847-9.
46. Verbeke K, Rozenski J, Cleynhens B, et al. Development of a conjugate of 99mTc-EC with aminomethylenediphosphonate in the search for a bone tracer with fast clearance from soft tissue. Bioconjug Chem 2002; 13: 16-22.
47. Ogawa K, Mukai T, Inoue Y, Ono M, Saji H. Development of a novel 99Tc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J Nucl Med 2006; 47: 20427.
48. Giannakenas C , Kalofonos HP, Apostolopoulos DJ, Zarakovitis J, Kosmas C, Vassilakos PJ. Preliminary Results of the Use of Re-186-HEDP for Palliation of Pain in Patients With Metastatic Bone Disease. Am J Clin Oncol 2000; 239(1): 83-8.
49. Scheffler J, Derejko M, Bandurski T, Romanowicz G. Application of rhenium-188 HEDP in bone metastases therapy. Nucl Med Rev 2003; 6 (1): 55-7.
50. Elder RC, Yuan J, Helmer B, Pipes D, Deutsch K, Deutsch E. Studies of the structure and composition of rhenium-1,1-hydroxyethylidenediphosphonate (HEDP) analogs of the radio-therapeutic agent 186ReHEDP. Inorg Chem 1997; 36(14): 3055-63.
51. Lam MG, De Klerk JM, Van Rijk PP. 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur J Med Mol Imaging 2004; 31: S162-S170.
52. Lin WY, Lin CP, Yeh SJ, et al. Rhenium-188 hydroxyethylidene diphosphonate: A new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med 1997; 24: 590-5.
53. Maxon III HR, Schroder LE, Washburn LC, et al. Rhenium-188(Sn)HEDP for the treatment of osseous metastases. J Nucl Med 1998; 39: 659-63.
54. Li S, Liu J, Zhang H, Tian M, Wang J, Zheng X. Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 2001; 26: 919-22.
55. Liepe K, Kropp J, Runge R, Kotzerke J. Therapeutic efficacy of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 2003; 89: 625-9.
56. Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tan-domized phase II trial with the new, high-energy radiopharmaceu tical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003; 21: 2869-75.
57. Zhang H, Tian M, Li S, Liu J, Tanada S, Endo K. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother Radiopharm 2003; 18: 71926.
58. Uehara T, Jin ZL, Ogawa K, et al. Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiophar-maceuticals for bones. Nucl Med Biol 2007; 34: 79-87.
59. Arano Y, Ono M, Wakisaka K, et al., Synthesis and biodistribution studies of 186Re complex of 1-hydroxyethylidene-1,1-diphosphonate for treatment of painful osseous metastases. Radio-isotopes 1995; 44: 514-22
60. De Winter F, Brans B, Van de Wiele C, Dierckx RA. Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma. Clin Nucl Med 1999; 24: 898-9.
61. Limouris GS, Skukla SK. Gastric uptake during Re-186 HEDP bone scintigraphy. Anticancer Res 1997; 17: 1779-81.
62. Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev 1999; 99: 2269-92.
63. Jansen DR, Zeevaart JR, Denkova A, Kolar ZI, Krijger GC. The Hydroxyapatite Chemisorption of N,N',N'-trimethylenephosphonate- polyethyleneimine (PEI-MP) Combined with Sn2+ or Sn4+. Langmuir 2009; 25(5): 2790-6.
64. Lam MG, Dahmane A, Stevens WH, van Rijk PP, de Klerk JM, Zonnenberg BA. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 2008; 35(4): 756-65.
65. Ogawa K, Mukai T, Arano Y, et al. Design of radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative. J Labelled Comp Radiopharm 2004; 47: 753-61.
66. Ogawa K, Mukai T, Arano Y, et al. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radio-pharmaceuticals. Bioconjug Chem 2005; 16: 751-7.
67. Ogawa K, Mukai T, Arano Y, et al. Rhenium-186-monoaminemonoamidedithiol- conjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol 2006; 33: 513-20.
68. Lam MGEH, Bosma TB, Van Rijk PP, Zonnenberg BA. 188Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. Eur J Nucl Med Mol Imaging 2009; 36: 1425-33.
69. Ricci S, Boni G, Pastina I, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Med Mol Imaging 2007; 34: 1023-30.
70. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 2003; 12: 298894.
71. Akerley W, Butera J, Wehbe T, et al. A multiinstitutional, concurrent chemoradiation trial of strontium-89 extramustine and vin-blastine for hormone refractory prostate carcinoma involving bone. Cancer 2002; 94: 1654-60.
72. Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43: 79-86.
73. Tu S, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 367: 336-41.
74. Logothetis C, Tu S, Navone N. Targeting prostate cancer bone metastases. Cancer 2003; 97: 785-8.
75. Pillai MRA, Chakraborty S, Das T, Venkatesh M, Ramamoorthy N. Production logistics of 177Lu for radionuclide therapy. Appl Radiat Isot 2003; 59: 109-18.
76. Das T, Chakraborty S, Sarma HD, Banerjee S, Venakatesh M. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy. Nucl Med Biol 2010; 37: 655-63.
77. Stillebroer A, Boerman O, Oosterwijk E, Mulders P, Oyen W. Ra-dioimmunotherapy with Lutetium-177 labeled monoclonal antibody cG250 in patients with advanced renal cell carcinoma. J Nucl Med 2008; 49: 20P.
78. Scholm J, Siler K, Milenic DE, et al. Monoclonal Antibody-based Therapy of a Human Tumor Xenograft with a 177Lutetium-labeled Immunoconjugate. Cancer Res 1991; 51: 2889-96.
79. Meredith RF, Partridge EE, Alvarez RD, et al. Intraperitoneal Radioimmunotherapy of Ovarian Cancer with Lutetium-177-CC49. J Nucl Med 1996; 37: 1491-6.
80. Pan MH, Gao DW, Feng J, et al. Biodistributions of 177Lu-and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunother-apy. Mol Imaging Biol 2009; 11 (3): 159-66.
81. Schlom J, Siler K, Milenic DE, et al. Monoclonal Antibody-based Therapy of a Human Tumor Xenograft with a 177Lutetium-labeled Immunoconjugate. Cancer Res 1991; 51: 2889-96.
82. Meredith RF, Partridge EE, Alvarez RD, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with Lutetium-177-CC49. J Nucl Med 1996; 37: 1491-6.
83. Das T, Chakraborty S, Unni PR, et al. 177Lu-labeled cyclic poly-aminophosphonates as agents for bone pain palliation. Appl Radiat Isot 2002; 57: 177-84.
84. Rutty Sola GA, Arguelles MG, Bottazzini DL, et al. Lutetium-177-EDTMP for bone pain palliation. Preparation, biodistribution and pre-studies. Publicado en Radiochim 2000; 3-4: 157-61.
85. Das T, Chakraborty S, Barnerjee S, et al. 177Lu-EDTMP: A new radiopharmaceutical for palliation of bone pain in cancer patients with skeletal metastases. Dr Homi Bhabha Centenary Year 2009; 305: 2-11.
86. Das T, Chakraborty S, Sarma HD, Banerjee S. 177Lu-DOTMP: A viable agent for palliative radiotherapy of painful bone metastasis. Radiochim Acta 2008; 96: 55-61.
87. Garnuszek P, Pawlak D, Licinska I. [EDTMP chelates with different radionuclides. Part I. Preparation and investigation of EDTMP chelates with: 153Sm, 177Lu, 99mTc, 51Cr, 113mIn, and 64Cu. Polish Probl Med Nucl 2001; 15(29): 63-70.
88. Garnuszek P, Pawlak D, Licinska I. EDTMP chelates with different radionuclides. Part II. Development of the radiopharmaceutical kit for preparation of EDTMP chelates with Lutetium-177 and technetium-99m. Polish Probl Med Nucl 2001; 15: 71-9.
89. Garnuszek P, Pawlak D, Licinska I, Kaminska A. Evaluation of a freeze-dried kit for EDTMP-based bone-seeking radiopharmaceuti-cals. Appl Radiat Isot 2003; 58: 481-8.
90. Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the a-emitter 223Ra: Adjuvant or alternative to conventional modalities. Clin Cancer Res 2006; 12: 6250s-7s.
91. Kennel SJ, Lankford T, Garland M, Sundberg JP, Mirzadeh S. Biodistribution of 225Ra citrate in mice: retention of daughter ra-dioisotopes in bone. Nucl Med Biol 2005; 32: 859-67.
92. Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature 1977; 266: 653-5.
93. Van Rooyen J, Szucs Z, Zeevaart JR. A possible in vivo generator 103Pd/103mRh-Recoil considerations. Appl Radiat Isot 2008; 66: 1346-9.
94. Yano Y, Chu P, Anger HO. Tin-117m: Production, chemistry and evaluation as a bone-scanning agent. Int J Appl Radiat Isot 1973; 24: 319-25.
95. Oster ZH, Som P, Srivastava SC, et al. The development and in-vivo behaviour of tin containing radiopharmaceuticals-II. Autora-diographic and scintigraphic studies in normal animals and in animal models of bone disease. Int J Nucl Med Biol 1985; 12(3): 17584.
96. Srivastava SC, Meinken GE, Richards P, et al. The development and in-vivo behaviour of tin containing radiopharmaceuticals-I. Chemistry, preparation, and biodistribution in small animals. Int J Nucl Med Biol 1985; 12(3): 167-74.
97. Swailem FM, Krishnamurthy GT, Srivastava SC, et al. In-vivo tissue uptake and retention of Sn-117m(4+)DTPA in a human subject with metastatic bone pain and in normal mice. Nucl Med Biol 1998; 25: 279-87.
98. Zimmerman BE, Cessna JT, Schima FJ. The standardization of the potential bone palliation radiopharmaceutical 117mSn(+4)DTPA. Appl Radiat Isot 1998; 49: 317-28.
99. Yang Y, Luo S, Pu M, et al. Labeling conditions, in vitro properties and biodistributions of various Sn-labeled complexes. Appl Radiat Isot 2005; 62: 597-603.
100. Claessens RAMJ, Kolar ZI. Affinity of tin(II) and tin(II) diphos-phonates for hydroxyapatite: An experimental and model study. Langmuir 2000; 16(3): 1360-7.
101. Zeevaart JR, Jarvis NV, Louw WKA, Jackson GE. Metal-ion spe-ciation in blood plasma incorporating the tetraphosphonate, N,N-dimethylenephosphonate-1- hydroxy-4-aminopropilydenediphosph-onate (APDDMP), in therapeutic radiopharmaceuticals. J Inorg Bi-ochem 2001; 83(1): 57-65.
102. Zeevaart JR, Louw WKA, Jarvis NV, Wagener JM. Comparison of the predicted behaviour of 153Sm, 166Ho and 117mSn containing bone agents, employing blood plasma models (ECCLES), with in vivo results as studied in animals. J Labelled Comp Radiopharm 2001; 44: s799-s801.
103. Zeevaart JR, Jansen DR, Botelho MF, et al. Comparison of the predicted in vivo behaviour of the Sn(II)-APDDMP complex and the results as studied in a rodent model. J Inorg Biochem 2004; 98: 1521-30.
104. Zeevaart JR, Louw WKA, Kolar ZI, Wagener JM, Jarvis NV, Claessens RAMJ. A thermodynamic approach, using speciation studies, towards the evaluation and design of bone-seeking radio-pharmaceuticals as illustrated for 117mSn(II)-PEI-MP. J Radioanal Nucl Chem 2003; 257(1): 83-91.
105. Zeevaart JR, Louw WKA, Kolar ZI, Kilian E, Jansen van Rensburg FE, Dormehl IC. Biodistribution and pharmacokinetics of variously molecular sized 117mSn(II)-polyethyleneiminomethyl phosphonate complexes in the normal primate model as potential selective therapeutic bone agents. Drug Res 2004; 54(6): 340-7.
106. Maeda H, Greish K, Fang J. The EPR effect and polymeric drugs: A paradigm shift for cancer chemotherapy in the 21st century. Adv Polym Sci 2006; 193: 103-21.
107. Jansen DR, Zeevaart JR, Kolar ZI, Djanasvili K, Peters JA, Krijger GC. 31P NMR study of the valence stability of tin in its 1-hydroxyethylene- diphosphonate (HEDP) and N,N',N'-trimethylenephosphonate-polyethyleneimine (PEI-MP) complexes. Polyhedron 2008; 27: 1779-86
108. Jansen DR, Krijger GC, Wagener J, et al. Blood plasma model predictions for the proposed bone-seeking radiopharmaceutical 117mSn]Sn(IV)-N,N',N'- trimethylenephosphonatepoly(ethyleneim-ine). J Inorg Biochem 2009; 103: 1265-72.
109. Dormehl IC, Louw WKA, Milner RJ, Kilian E, Schneeweiss FHA. Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model. Drug Res 2001; 51(3): 258-63.
110. Louw WKA, Dormehl IC, Van Rensburg AJ, et al. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model. Nuc Med Biol 1996; 23(8): 935-40.
111. Stabin MG. Developments in the internal dosimetry of radiophar- maceuticals. Radiat Prot Dosimetry 2003; 105: 575-80.
112. Stabin MG, Eckerman KF, Bolch WE, Bouchet LG, Patton PW. Evolution and Status of Bone and Marrow Dose Models. Cancer Biother Radiopharm 2002; 17(4): 427-33.
113. Wessels BW, Bolch WE, Bouchet LG, et al. Bone marrow dosime-try using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med 2004; 45: 1725-33.
114. De Klerk JMH, Van Dieren EB, Van het Schip AD, et al. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med 1996; 37: 38-41.
115. Valdes Olmos RA, Hoefnagel CA. Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities? Eur J Nucl Med Mol Imaging 2004; 31: 929-31.